Abbott Laboratories Q2 Earnings Preview: A Contrarian Buy Opportunity Worth Considering

Impact · against what's priced in

Abbott Laboratories (ABT) is positioned for a valuation rerating driven by a strategic entry into cancer diagnostics and concrete 2026 growth guidance. While the Exact Sciences (EXAS) acquisition creates a short-term EPS headwind, the long-term revenue potential provides a fundamental catalyst for the stock.

ABT+0.40: No priced-in read yet

Abbott Laboratories Q2 Earnings Preview: A Contrarian Buy Opportunity Worth Considering

What matters in this story

Semiconductor ETFs to Buy as Qualcomm Plunges Despite Q4 Earnings Beat

Abbott Laboratories Q2 Earnings Preview: A Contrarian Buy Opportunity Worth Considering

What matters in this story

Semiconductor ETFs to Buy as Qualcomm Plunges Despite Q4 Earnings Beat

How each ticker is affected

Connected tickers

Track these names every morning.

ISRG Agrees to $450M Settlement: What Does It Mean for Investors?

Intel stock faces $13 billion Nvidia dilemma: what happens if Jensen Huang goes?

Palantir's Real Washington Risk Isn't the Budget—It's Oversight

Peloton Q1: Trades At A Discount Despite Subscriber Decline

Abbott Laboratories Q2 Earnings Preview: A Contrarian Buy Opportunity Worth Considering

What matters in this story

Next reads from the same story arc

Semiconductor ETFs to Buy as Qualcomm Plunges Despite Q4 Earnings Beat

Abbott Laboratories Q2 Earnings Preview: A Contrarian Buy Opportunity Worth Considering

What matters in this story

Next reads from the same story arc

Semiconductor ETFs to Buy as Qualcomm Plunges Despite Q4 Earnings Beat

How each ticker is affected

Connected tickers

Track these names every morning.

ISRG Agrees to $450M Settlement: What Does It Mean for Investors?

Intel stock faces $13 billion Nvidia dilemma: what happens if Jensen Huang goes?

Palantir's Real Washington Risk Isn't the Budget—It's Oversight

Peloton Q1: Trades At A Discount Despite Subscriber Decline